Marker Therapeutics, Inc. (MRKR)

Market Cap	37.75M
Revenue (ttm)	3.31M
Net Income (ttm)	-8.24M
Shares Out	8.90M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,299
Open	4.260
Previous Close	4.100
Day's Range	4.050 - 4.260
52-Week Range	0.760 - 9.680
Beta	1.54
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2024

About MRKR

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leuke...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Juan F. Vera M.D.
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: MRKR

Financial Performance

In 2023, MRKR's revenue was $3.31 million, a decrease of -5.76% compared to the previous year's $3.51 million. Losses were -$8.24 million, -72.48% less than in 2022.